Skip to content

Investments at other companies

Alkermes logo
AlkermesALKS
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
iRhythm Holdings, Inc.
 logo
iRhythm Holdings, Inc. IRTC

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$1.99B-14.9%

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermInvestments.

The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harmony Biosciences Holdings, Inc.'s investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s investments?
Harmony Biosciences Holdings, Inc. (HRMY) reported investments of $229.56M in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s investments changed year-over-year?
Harmony Biosciences Holdings, Inc.'s investments increased by 122.3% year-over-year, from $103.25M to $229.56M.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s investments?
Over 3 years (2022 to 2025), Harmony Biosciences Holdings, Inc.'s investments has grown at a 68.1% compound annual growth rate (CAGR), from $22.57M to $107.13M.